Boxer Capital’s Sarepta Therapeutics SRPT Stock Holding History

Boxer Capital’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-650,000	Closed	-$81.2M	–	50
2024 Q3	$81.2M	Hold	650,000	–	–	3.98%	8
2024 Q2	$103M	Hold	650,000	–	–	5.41%	6
2024 Q1	$84.1M	Hold	650,000	–	–	4.16%	8
2023 Q4	$62.7M	Buy	650,000 +50,000	+8%	+$4.8M	3.12%	13
2023 Q3	$72.7M	Hold	600,000	–	–	3.87%	8
2023 Q2	$68.7M	Sell	600,000 -175,000	-23%	-$22.6M	3.19%	9
2023 Q1	$107M	Buy	+775,000	New	+$101M	5.25%	4
2022 Q4	–	Sell	-200,000	Closed	-$22.1M	–	75
2022 Q3	$22.1M	Hold	200,000	–	–	1.24%	29
2022 Q2	$15M	Buy	+200,000	New	+$14.7M	0.95%	36
2020 Q1	–	Sell	-225,000	Closed	-$29M	–	67
2019 Q4	$29M	Sell	225,000 -325,000	-59%	-$32.8M	1.64%	16
2019 Q3	$41.4M	Buy	+550,000	New	+$65M	3%	10
2018 Q3	–	Sell	-375,000	Closed	-$49.6M	–	27
2018 Q2	$49.6M	Buy	+375,000	New	+$35.4M	5.61%	8

Other funds holding SRPT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Boxer Capital's SRPT Position: Q4 2024 in Review

Boxer Capital sold out of Sarepta Therapeutics (SRPT) in Q4 2024, closing a stake of 650,000 shares — an estimated $81.2M sold.

Boxer Capital first reported a position in SRPT in Q2 2018 and held it in 12 quarters. The position peaked at $107M in Q1 2023. 464 funds tracked by Wall St. Rank hold SRPT as of Q4 2024.

Boxer Capital reported no remaining Sarepta Therapeutics position as of Q4 2024 after selling out during the quarter.
Boxer Capital sold 650,000 Sarepta Therapeutics shares in Q4 2024, an estimated $81.2M.
Boxer Capital first reported a position in Sarepta Therapeutics in Q2 2018 and held it in 12 quarters.
Boxer Capital's Sarepta Therapeutics position peaked at $107M in Q1 2023.
464 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q4 2024.

Based on Boxer Capital's 13F filing for Q4 2024.